Concepts
Treatment-Resistant Depression (TRD)
Summary
Treatment-resistant depression is generally defined as depression that has failed to respond to at least two adequate antidepressant trials. Affects roughly 30% of people with majo…
Research notes
Context, reporting, and structured background for this dossier.
Treatment-resistant depression is generally defined as depression that has failed to respond to at least two adequate antidepressant trials. Affects roughly 30% of people with major depressive disorder. Psilocybin has shown consistent symptom reduction in open-label studies; controlled Phase 2/3 trials show meaningful but smaller effects.
Related entities
Other dossiers that help connect this page to the wider reporting record.
- Psilocybin
Psilocybin is the prodrug active compound in psilocybin mushrooms, converted in the body to psilocin. Under investigation for treatment-resistant depression, PTSD, OCD, alcohol use…
- Compass Pathways
Compass Pathways is one of the most advanced public-company psilocybin developers, with a large Phase 3 COMP360 program in treatment-resistant depression and an FDA-authorized PTSD IND path.
- Cybin, now Helus Pharma
Cybin, now Helus Pharma, is a biopharmaceutical company developing deuterated serotonergic compounds, with HLP003/CYB003 now positioned inside a Phase 3 depression program.
- FDA
The U.S. Food and Drug Administration is the gatekeeper for psychedelic drug development in the United States, from IND clearance through advisory committee review and any eventual approval or rejection.